AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00303212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: Participants in the intervention group are instructed to make a daily toll-free call to an automated telemonitoring system being provided by Pharos Innovations® (Chicago, IL) for 6 months.On each call patients hear a pre-recorded voice that goes through a series of questions about symptoms and the patient's daily weight. Information from the telemonitoring system is automatically downloaded to a secure Internet site for review by clinicians at each practice site.
Study NCT04588896 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring
Description: Abbott Freestyle Libre CGM for 8 weeks in adjunct to lifestyle modification programme
Study NCT03240224 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cancer ablation
Description: Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
Study NCT03240224 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cancer ablation
Description: Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
Study NCT04588896 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification programme
Description: Lifestyle modification programme
Study NCT04588896 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle modification programme
Description: Lifestyle modification programme
Study NCT02501759 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3 Tesla Magnetic Resonance Imaging
Description: Undergo diagnostic multiparametric endorectal MRI with gadodiamide contrast
Study NCT02501759 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Gadodiamide
Description: Given IV
Study NCT02501759 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multiparametric Magnetic Resonance Imaging
Description: Undergo diagnostic multiparametric endorectal MRI with gadodiamide contrast
Study NCT02501759 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transrectal Biopsy
Description: Undergo transrectal MRI-guided biopsy
Study NCT02501759 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-Guided Prostate Biopsy
Description: Undergo TRUS-guided biopsy
Study NCT02788006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg
Study NCT02904109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triflusal
Description: Once daily oral administration of 600 mg triflusal Disgren® for 8 days.
Study NCT02904109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Once daily oral administration of placebo mannitol for 8 days.
Study NCT00982982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THC and Iomazenil
Description: * Iomazenil: 3.7 μg/kg intravenously over 10 minutes~* Delta-9-THC (0.015 mg/kg = 1.05 mg in a 70kg individual), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or joint. It is administered intravenously for 10 minutes.
Study NCT00982982 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (control)
Description: Control: small amount of alcohol intravenous (quarter teaspoon), with no THC
Study NCT01951092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text messaging
Study NCT00253279 — intervention group
Intervention type: PROCEDURE
Intervention: PET Scans
Description: Healthy volunteers will undergo one PET Scan; bur patients will undergo a maximum of 3 PET scans over 2 years after injury; a maximum of 2 will be done while inpatient; one after d/c.
Study NCT01410461 — intervention group
Intervention type: DEVICE
Intervention: quantitive sensory testing
Description: Mechanical pain threshold: Threshold will be assessed, by using the von Frey filaments. The lowest gram weight capable of inducing pain in two of three trials will be considered as a pain threshold Heat pain threshold (HPT): HPT will be measured using thermal sensory analyzer
Study NCT01410461 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound testing
Description: Morphological measures of the pelvic muscles: Using a 3D 4-8MHz abdominal probe ultrasound testing will be performed. The following parameters will be measured: (1) anteroposterior hiatal diameter; (2) lateral hiatal diameter; (3) levator ani thickness and length at 3 o'clock and 9 o'clock; (4) length of the obturator (5) length of the pubococcygeus muscle; (6) obturator thickness.
Study NCT02591680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular training
Study NCT02591680 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle strengthening
Study NCT02591680 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensorimotor
Study NCT01416896 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodialysis using the standard venous needle
Description: Hemodialysis using the standard venous dialysis needle
Study NCT01416896 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodialysis using a new venous needle, the BME needle
Description: Hemodialysis using a new venous dialysis needle or the BME needle
Study NCT01416896 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodialysis using a new venous needle, the BME needle
Description: One hemodialysis using a new venous needle, the BME needle
Study NCT01416896 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodialysis using the standard venous needle
Description: One hemodialysis using the standard venous needle
Study NCT04415385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg, intravenous infusion for 30 minutes (including the time of the tube, the overall infusion time is not shorter than 20 minutes, no longer than 60 minutes), once every 2 weeks.
Study NCT04415385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 250 mg, orally once a day. Take about half an hour after a meal with warm water.
Study NCT01227408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin, paclitaxel poliglumex, capecitabine, cyclophosphamide, methotrexate
Description: doxorubicin 20mg/m2 weekly x 12 wks, cyclophosphamide 50 mg PO qd x 12 wks, methotrexate 2.5 mg PO bid d1,2 wkly x 12. One week later paclitaxel poliglumex 135mg/m2 IV every 3 wks plus capecitabine 825 mg/m2 PO bid x 14days x 4 cycles
Study NCT04356339 — intervention group
Intervention type: DRUG
Intervention: Interferon-beta-1b (BETASERON, BAY 86-5046)
Description: Using the BETACONNECT autoinjector and myBETAapp as prescribed by the physician
Study NCT04325464 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEAR-003A
Description: PEAR-003A delivers CBT-I through a decentralized clinical trial open to participants with chronic insomnia
Study NCT01397565 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy
Study NCT01397565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minilaparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy performed using minilaparoscopic instruments
Study NCT02973360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic Acid
Description: Oral Capsule
Study NCT02973360 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Capsule
Study NCT02337478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Liposome
Description: Given via injection
Study NCT02337478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02936622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zilver® Paclitaxel-Eluting Peripheral Stent
Description: Paclitaxel belongs to the Taxane drug class and coated on the stent at a much lower dose than when administered as a chemotherapy agent.
Study NCT02936622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zilver® Paclitaxel-Eluting Peripheral Stent with slower-dissolving polymer-free paclitaxel coating
Description: Paclitaxel belongs to the Taxane drug class and coated on the stent at a much lower dose than when administered as a chemotherapy agent.
Study NCT02936622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zilver® Paclitaxel-Eluting Peripheral Stent with higher-dose polymer-free paclitaxel coating
Description: Paclitaxel belongs to the Taxane drug class and coated on the stent at a much lower dose than when administered as a chemotherapy agent.
Study NCT03910348 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole-body vibration exercise
Description: The WBV training consisted of a high frequency (30-40 Hz) vibration stimulus at a low setting on a Power Plate pro5 vibration platform (Performance Health Systems, LLC, Northbrook, IL, USA).
Study NCT03240224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Life information rehabilitation therapy
Description: Each treatment: one bottle solution each day, consecutive 3 months, oral administration
Study NCT03240224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Life information rehabilitation therapy
Description: Each treatment: one bottle solution each day, consecutive 3 months, oral administration
Study NCT03258008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Utomilumab given by vein on Cycle 1 Day 1. Cycle 1-2 100 mg, Cycle 3-12 50 mg until progressive disease, toxicity, or 1 yr.
Study NCT03258008 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISA101b
Description: ISA101b 100 mcg/peptide given subcutaneously every 4 weeks x 3 doses beginning cycle 1 day 1.
Study NCT00709007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Directly Administered Antiretroviral Therapy (DAART)
Description: Participants are observed taking HIV medications by study staff on days when they receive opioid agonist therapy (sub-lingual buprenorphine) at the clinic.
Study NCT00709007 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SAT
Description: Participants take their HIV medications by themselves.
Study NCT01023841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bimatoprost ophthalmic solution 0.03%
Description: One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
Study NCT01023841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Sterile Solution
Description: One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
Study NCT01718145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Study NCT01718145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunaprevir
Study NCT01718145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Study NCT01718145 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pegIFNα-2b
Study NCT01718145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telaprevir
Study NCT00772824 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: 2g/kg body weight twice daily in divided doses for 5 days
Study NCT00772824 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: IV Glutamine
Description: 50 ml of 20% glutamine IV before chemotherapy
Study NCT02672358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Oral Dabrafenib 150 mg BID
Study NCT02672358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Oral Trametinib 2 mg QD
Study NCT04106362 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV
Study NCT04106362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study NCT04106362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT04106362 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04106362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04106362 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04106362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04106362 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT04106362 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT01004601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: patients at one university-affiliated hospital received low dose single docetaxel (30 mg/m2 on days 1 and 8 every 3 weeks)following failure of previous treatment stage IIIb/IV NSCLC.
Study NCT01004601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: patients at one university-affiliated hospital received pemetrexed (500 mg/m2 every 3 weeks) following failure of previous treatment stage IIIb/IV NSCLC.
Study NCT04015518 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Spesolimab
Description: Subcutaneous injections of Spesolimab starting at week 16, for a total treatment time until week 52.
Study NCT04015518 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Subcutaneous injections of placebo matching Spesolimab from week 0 to 16.
Study NCT04015518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Subcutaneous injections of Spesolimab in a low dose scheme for a total treatment time of 52 weeks.
Study NCT04015518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Subcutaneous injections of Spesolimab in a medium-low dose scheme for a total treatment time of 52 weeks.
Study NCT04015518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Subcutaneous injections of Spesolimab in a medium-high dose scheme for a total treatment time of 52 weeks.
Study NCT04015518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Subcutaneous injections of Spesolimab in a high dose scheme for a total treatment time of 52 weeks.
Study NCT01651338 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: The patients went through acupuncture for 8 -10 sessions and either once or two times a week. The number and the place of needles were 8 -12 for each patient which were located on the right place.
Study NCT03006068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib (ABT-494)
Description: Upadacitinib (ABT-494) will be administered orally.
Study NCT03006068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally.
Study NCT01094652 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole grain diet
Description: Subjects were told to consume three different kinds of study food each day. The goal was an intake of greater than or equal to 80 g of whole grains per day.
Study NCT01094652 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Refined grain diet
Description: The refined grain food products were matched as closely as possible to the foods contained in the whole grain diet. Subjects were told to consume three different kinds of study food each day.
Study NCT02923245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: point-of-care ultrasound
Study NCT00648505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glipizide and Metformin HCl Tablets 5 mg/500 mg
Description: 5/500mg, single dose fed
Study NCT00648505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metaglip® Tablets 5 mg/500 mg
Description: 5/500mg, single dose fed
Study NCT03328494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172722
Description: Oral capsules
Study NCT03328494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion
Study NCT00005601 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT00005601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00005601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study NCT00005601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study NCT00005601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sargramostim
Study NCT03910348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-impact exercise
Description: In the high-impact exercise program, the patients were asked to jump using a jump-rope at the beginning of each session
Study NCT01863641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcitriol
Description: Patients will receive calcitriol at a fixed dose of 0.25 µg (one oral pearl) daily.
Study NCT01863641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Patients will receive placebo similar to intervention (shape, color and design) 1 oral unit daily.
Study NCT03403621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentamidine Isethionate
Description: Approximately 1.8 mL single dose delivered as topical formulation containing 2% topical pentamidine in silicone-containing base.
Study NCT03403621 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No active ingredient. Approximately 1.8 mL single dose delivered as topical silicone compounding base only.
Study NCT00943176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: 100 mg tablets of modafinil or matched placebo will be given for a total of 12 weeks. Patients will be instructed to start one capsule once daily (modafinil or placebo), and dose will be titrated according to tolerability and response.
Study NCT00943176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Modafinil
Description: 100 mg tablets of modafinil or matched placebo will be given for a total of 12 weeks. Patients will be instructed to start one capsule once daily (modafinil or placebo), and dose will be titrated according to tolerability and response.
Study NCT03066856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: The main aim of the trial is to reduce serum levels of IGF-I and IRm with a a low- calorie and low-protein diet. In humans, calorie restriction alone does not seem to significantly lower IGF-I; protein restriction is also required. In detail, recommendations for participants included in the intervention arm include:~* reducing protein intake, mainly milk and animal protein (except fish), down to 10-12% of total calorie intake.~* reducing high glycemic index food and high insulinemic foods.~* reducing sources of saturated fat (red and processed meat, milk and dairy products).~* eating mostly food of plant origin, with a wide variety of seasonal products.
Study NCT01038414 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Extended Duration Behavioral Smoking Cessation Counseling
Description: Subjects are randomized to one of 3 behavioral treatments: (1) Brief Duration (3 month) smoking-cessation counseling; (2) Moderate Duration (6 month) counseling; or (3) Extended Duration (12 month) counseling
Study NCT01038414 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Extended Duration Behavioral Smoking Cessation Counseling
Description: Subjects are randomized to one of 3 behavioral treatments: (1) Brief Duration (3 month) smoking-cessation counseling; (2) Moderate Duration (6 month) counseling; or (3) Extended Duration (12 month) counseling
Study NCT05936541 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Bifidobacterium Bifidum PRL2010
Description: Probiotic supplement
Study NCT05936541 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: No probiotic supplementation
Study NCT01229033 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation
Description: Ablation of atrial tachycardia
Study NCT01229033 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardioversion
Description: Cardioversion of atrial tachycardia